1. [Observational survey of the French Urological Association evaluating intermittent hormonal modalities treatment in prostate cancer in France].
- Author
-
Salomon L, Ploussard G, Coloby P, Kouri G, Lebret T, Méjean A, Prunet D, and Soulié M
- Subjects
- Aged, Androgen Antagonists economics, Antineoplastic Agents, Hormonal economics, Drug Administration Schedule, France, Health Surveys, Humans, Male, Middle Aged, Neoplasm Staging, Patient Selection, Prostatectomy, Prostatic Neoplasms blood, Prostatic Neoplasms economics, Prostatic Neoplasms therapy, Radiotherapy, Adjuvant, Surveys and Questionnaires, Treatment Outcome, Androgen Antagonists therapeutic use, Antineoplastic Agents, Hormonal therapeutic use, Biomarkers, Tumor blood, Prostate-Specific Antigen blood, Prostatic Neoplasms drug therapy, Quality of Life, Urology
- Abstract
Objective: To assess clinical practice of intermittent hormone therapy (IHT) among urologists members of the French Association of Urology., Methods: Internet-based observational survey evaluating IHT modalities in prostate cancer using questionnaire sent to 941 urologists., Results: Two hundred and sixty nine urologists participated in the survey (response rate 28.6 %) including 90.3 % prescribing IHT. The main reasons for IHT were improvement of quality of life in 94.2 %, clinical tolerance in 73.7 %, decreased costs and oncological equivalence in 44 %. The indications were localized prostate cancer (low risk 22.6 %, intermediate 19.8 %, high 14 %), locally advanced (59.7 %), metastatic (63.4 %), biochemical recurrence after local treatment (prostatectomy 62.1 %, radiotherapy 73.7 %). A PSA <2 ng/mL was considered as the threshold for androgen deprivation therapy break in 70 % of cases regardless of the IHT indication. The PSA threshold selected for the re-initiation of treatment was 4 ng/mL in 37.9 % and 10 ng/mL in 36.6 % of cases. The cycle of IHT was 6 months in 60 % of cases., Conclusion: This survey provided a snapshot of the practice of IHT in France. Even in the absence of level of evidence 1 trials in the literature, most urologists used IHT in their clinical practice, for many indications, especially in case of biochemical recurrence after local treatment., Level of Proof: 3., (Copyright © 2013 Elsevier Masson SAS. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF